Can Borui Biotech stand out in the treatment of lymphoma with the launch of its first biologically innovative drug, Zebedumab?
AD |
21st Century Business Herald reporter Zhu Yiyi reports from ShanghaiThe launch of this new drug is not only a major milestone in the development of Brilliant Biology, but also provides new treatment options for domestic lymphoma patients.Multiple indicators with significant clinical efficacyAccording to public information, lymphoma is one of the common hematological malignancies
21st Century Business Herald reporter Zhu Yiyi reports from Shanghai
The launch of this new drug is not only a major milestone in the development of Brilliant Biology, but also provides new treatment options for domestic lymphoma patients.
Multiple indicators with significant clinical efficacy
According to public information, lymphoma is one of the common hematological malignancies. At present, the incidence rate of lymphoma in China is about 6.68/100000 people, with more than 100000 new cases every year. Among them, B-cell non Hodgkin lymphoma is one of the common types, and the number of cases and deaths are increasing year by year.
In addition, the market prospects for CD20 targets are broad.
According to Frost&Sullivan's report, in 2020, the market size of anti CD20 monoclonal antibodies in China will be 3.5 billion yuan, which is expected to reach 9.8 billion yuan and 22 billion yuan in 2025 and 2030, respectively. The compound annual growth rate from 2020 to 2025 is 23.1%, and the compound annual growth rate from 2025 to 2030 is 17.5%.
Against the above background, numerous pharmaceutical companies are vying to layout around the CD20, a "old but new" target.
In the face of fierce market competition, what are the advantages of Borui Bio's Zebedumab? Can we break through the tight encirclement?
"In 2007, we cooperated with Academician Shen Beifen, an academician of the CAE Member and an academic leader of molecular immunology, and his team to develop Zebetumab. After 16 years of research and development, the biological innovative drug was finally approved for marketing in 2023." On the sidelines of the national marketing conference of Anruixizebetumab, Wang Haibin, CEO of Braui Biology, pointed out in an interview with reporters from 21st Century Business Herald.
According to Wang Haibin, "Compared to other anti CD20 monoclonal antibody products, the cytotoxic effect (ADCC) mediated by Zebedizumab antibody is stronger, and it has a larger steady-state distribution volume, which can produce a more lasting clearance effect on B cells, thereby exerting better drug effects.
The commercialization progress and indication expansion of Zebedizumab are receiving attention
At this stage, Wang Haibin revealed that he will provide patients with greater access through charitable assistance.
For the development plan of other indications of zebetozumab, Wang Haibin said that the company would further expand the relevant indications of zebetozumab, "such as developing relevant indications for some subtypes of other B-cell lymphoma; in the future, we will also promote the field of autoimmunity, including developing relevant indications for primary immune thrombocytopenia (ITP), Rheumatoid arthritis (RA) and nephrology".
Focusing on self immunity and tumor pipelines
As an innovative biopharmaceutical enterprise, Borui Biotech focuses on the fields of autoimmune and tumor treatment, and differentiates its innovation pipeline. At present, the company has more than 20 main research products, of which more than 10 have entered the clinical stage, and 6 have been commercialized and listed.
The shareholders of Borui Biotech include well-known investment institution Taimeng Investment, A-share listed company Haizheng Pharmaceutical (600267. SH), and Taizhou State owned Asset Investment Group Co., Ltd.
In addition, BRY812, a class 1 new drug of Brevibios, is a new anti LIV-1ADC drug for breast cancer and the second targeted LIV-1ADC drug entering the clinical stage in the world.
For more information, please download the 21 Finance APP
Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])
Mobile advertising space rental |
Tag: the of Can Borui Biotech stand out in treatment
Lai Rong High Speed Railway Begins Cold Sliding Test of Contact System
NextProof of concept New Configurable Chip free RFID Strain Sensor
Guess you like
- Detail
-
Apple Phones Banned: Why Has the Once-Shining Star Fallen From Grace?Detail
2024-10-01 12:19:49 1
-
AI Audio Incident: Hefei Police Unravel the Truth Behind Online Rumors, A Clash of Technology and JusticeDetail
2024-09-30 22:45:17 1
-
Yadea Guaneng E8: The "Rolls Royce" of Electric Vehicles, A Perfect Blend of Performance and IntelligenceDetail
2024-09-30 22:05:41 1
-
The Chaos of Live Streaming E-commerce: Deep Reflections Triggered by the San Zhi Yang False Advertising IncidentDetail
2024-09-30 19:43:26 1
-
New E-commerce Development Trends: Regulation and Empowerment, Boosting High-Quality Development of the Digital EconomyDetail
2024-09-29 18:03:14 1
- Detail
- Detail
-
Maoyan Entertainment Unveils "Shenbi Malia": AI-Powered Screenplay Creation with One-Click Dynamic Storyboard GenerationDetail
2024-09-27 15:52:43 1
-
Huawei Cloud and CAICT Jointly Released Two Value Reports to Empower City Digital Transformation and UpgradingDetail
2024-09-27 15:29:32 1
-
Huawei MateXT: Scalpers Caught in the Crossfire, High Prices Unrelenting, Can Production Ramp-Up Offer Relief?Detail
2024-09-27 14:40:15 11
-
10G-PON Leads Digital Transformation: 2024 International Information and Communication Exhibition Focuses on Innovative DevelopmentDetail
2024-09-27 14:00:08 1
-
The Light of Science Illuminates Dreams: The Path of Science Popularization at the Shandong Science and Technology MuseumDetail
2024-09-27 11:59:09 11
-
The Huawei Chip Dispute: A Balancing Act Between Independent Innovation and Open CollaborationDetail
2024-09-27 09:34:01 11
-
"Playing it Safe": Li Pao'er's Exit from Sanzhiyang, the Dilemma of "Siege" in Internet Celebrity EconomyDetail
2024-09-27 09:31:55 1
- Detail
-
From "Catching Up" to "Surpassing": The "Golden Age" of China's Precision Instrument DevelopmentDetail
2024-09-25 14:16:48 21
-
Huawei's "Closedness" and "Science": A Debate About the Direction of Technological DevelopmentDetail
2024-09-25 13:43:01 11
- Detail
- Detail